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Abstract
Acute kidney injury (AKI) is a serious complication of cardiovascular surgery. While some non-
experimental studies suggest statin use may reduce post-surgical AKI, methodological differences
in study designs leave uncertainty regarding the reality or magnitude of the effect. We estimated
the effect of pre-operative statin initiation on post-coronary artery bypass graft (CABG) AKI using
an epidemiologic approach more closely simulating a randomized controlled trial in a large CABG
patient population. We utilized healthcare claims from large, employer-based and Medicare
insurance databases for the years 2000 – 2010. To minimize healthy user bias, we identified
patients undergoing non-emergency CABG who either newly initiated a statin within 20 days prior
to surgery or were unexposed for 200+ days prior to CABG. AKI was identified within 15 days
following CABG. We calculated multivariable adjusted risk ratios (RR) and 95% confidence
intervals (CI) with Poisson regression. Analyses were repeated using propensity score methods
adjusted for clinical and healthcare utilization variables. We identified 17,077 CABG patients.
Post-CABG AKI developed in 3.4% of statin initiators and 6.2% of non-initiators. After
adjustment, we observed a protective effect of statin initiation on AKI (RR = 0.78, 95% CI 0.63,
0.96). This effect differed by age: ≥65 years, RR=0.91 (95% CI: 0.68, 1.20); <65 years, RR=0.62
(95% CI: 0.45, 0.86), although AKI was more common in the older age group (7.7 vs. 4.0%). In
conclusion, statin initiation immediately prior to CABG may modestly reduce the risk of post-
operative AKI, particularly in younger CABG patients.
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Statins may have anti-inflammatory1 and endothelial stabilizing2 pleiotropic effects with
potential benefits on kidney function3, motivating investigation for protective effects against
post-surgical kidney injury3–15. However, studies have employed widely varying definitions
of pre-operative statin use, including: prescribed statin use at the time of surgery4–6,8;
administration the day of or the day before surgery11,12,15; or pharmacy dispensing within
90 days prior to CABG14. Many of these definitions fail to consider history or duration of
statin use, which may introduce bias due to the healthy user effect16 whereby differences in
healthy behaviors between long-term medication users and non-users may lead to
exaggerated estimates of the benefits of preventive medications. These important
methodological concerns limit the ability to distinguish whether observed results are direct
beneficial effect of statins, or result from unmeasured behavioral differences in long-term
users of statins. Yet, acute kidney injury (AKI) remains a serious complication of coronary
bypass grafting (CABG), resulting in both short- and long-term consequences, including
chronic kidney disease (CKD), end-stage renal disease, or death17. Understanding the effect
of pre-operative statin use could allow clinicians to modify the risk of an outcome for which
there are currently no proven interventions. In a cohort of patients undergoing planned
CABG surgery, we compared post-surgery AKI risk among patients initiating a statin
immediately prior to surgery to patients not initiating statins using a modern epidemiologic
study design and analysis aimed at minimizing confounding bias.
Methods
Individuals undergoing CABG surgery between the years 2000 to 2010 were identified in
Thomson Reuters’ MarketScan® Commercial Claims and Encounters and Medicare
Supplemental and Coordination of Benefits databases (Thomson Reuters (Healthcare) Inc.,
2011). These databases are a compilation of insurance billing data for employees,
dependents and retirees from across the United States with employer-based primary or
Medicare supplemental insurance coverage (ages ≥65 years). Adjudicated, paid inpatient,
outpatient, and pharmacy claims, as well as enrollment information, are included in the
databases. This study was exempted from further review by the University of North Carolina
Institutional Review Board.
All patients ≥18 years with inpatient procedure claims for CABG, having 200 days of
continuous plan enrollment prior to hospital admission for CABG, were identified. If an
individual had multiple eligible CABG surgeries, only the first was considered. The 20 days
immediately prior to the date of hospital admission were considered the exposure window,
during which statin initiation was assessed. The 180 days prior to the exposure window were
considered the washout period, during which the absence of any statin prescription was
required (see Figure 1). We required at least 1 pharmacy claim for any non-statin medication
during the washout period to ensure pharmacy benefit utilization.
Patients with inpatient or outpatient diagnosis codes for AKI, unspecified renal failure, or
end-stage renal disease in the 200 days before CABG surgery were excluded. To restrict to
planned CABG procedures by removing individuals with emergency surgeries, we excluded
patients with: inpatient claims for MI or unstable angina during the 20-day exposure period;
CABG occurring after the fifth day of hospitalization; or an angiogram in the 3 days prior to
CABG surgery.
Statin initiation was defined as having a pharmacy dispensing claim for any statin during the
exposure window without any statin claims during the preceding baseline period. Non-users
had no observable statin use during the exposure or baseline windows and were required to
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have an outpatient physician’s office visit during the exposure window to ensure healthcare
utilization.
Baseline covariates for multivariable regression and propensity score models included
claims for diagnoses, procedures, prevalent medication use, and pre-operative initiation of
other, non-statin medications. Included covariates are shown in Table 1. Baseline diagnoses
and procedures were assessed in the 200 days prior to hospital admission for CABG and
during the hospitalization up to the day of surgery, and included: age; sex; year of surgery;
number of grafts in surgery; diagnoses of cardiovascular conditions; indicators of CVD
management; acute cardiovascular events and procedures; evidence of renal conditions;
number of emergency department visits; and number of hospitalizations. Claims for
medications during the washout period were considered prevalent medication use. If the
medications were newly initiated during the exposure window without use during the
washout period, the medications were considered newly-initiated and considered separately
in the analysis.
Inpatient claims in the 15 days post-CABG were searched for ICD-9-CM diagnosis codes
for AKI (584.5 – 584.9). Sensitivity analyses were performed employing a broader
definition of kidney failure (any of the following diagnosis codes: acute renal failure, 584.5
—584.9; end stage renal disease, 585.6; or unspecified renal failure, 586).
We estimated the association between statin initiation and AKI using multivariable Poisson
regression, resulting in adjusted risk ratios (RR) and 95% confidence intervals (CI)18. We
also performed regression analyses employing stabilized inverse probability of treatment
weighting (IPTW)19. Multivariable logistic regression was used to estimate the predicted
probability of initiating a statin, or propensity score (PS), for each individual in the sample
using the pre-specified covariates described above. To exclude patients treated contrary to
prediction as their extreme weights may disproportionately influence the effect measure
estimate20, we trimmed individuals with a PS less than the 1st percentile of the treated, or
greater than the 99th percentile of the untreated. The PS was then used to calculate the IPTW
in the remaining patients, and the weights were applied to a Poisson regression model.
Lastly, we performed 1-to-1 PS matching using a greedy matching algorithm21 where non-
users were matched to statin initiators by PS to the fifth decimal place, if possible. We then
estimated RR using regression models in the remaining matched individuals.
Models were run separately in the 2 databases: commercial insurance (ages 40–64 years)
and Medicare supplementary insurance (ages ≥65 years). We also repeated the analyses in
pre-specified subgroups—by gender, in those without CKD, and older age. Analyses were
performed using SAS 9.2 (SAS Institute Inc., Cary, NC).
Sensitivity analyses were performed by varying the length of the exposure window before
CABG (10 to 30 days) to observe if the effect may be dependent on the length of time on
statin prior to CABG. To estimate the extent to which medication initiation is simply a
proxy for better pre-surgical care, the entire analysis was repeated considering beta-blocker
initiation as a negative control exposure22 rather than statin initiation. Beta-blockers are
preventive cardiovascular medication with a similar behavioral profile and user population
as statins, but they are not thought to confer a protective effect against post-operative AKI.
Therefore, if a protective effect was observed among the beta-blocker initiators, it can be
assumed that our study design did not adequately address the healthy user effect and other
sources of confounding bias.
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We identified 149,696 individuals with CABG surgeries with 200 days of baseline
enrollment. After applying exclusion criteria, our sample consisted of 17,077 patients: 3,085
of whom newly initiated a statin within 20 days prior to CABG admission, and 13,992 who
were free of any statin use. For the distribution of day of statin initiation prior to CABG
among the initiators, see Figure 2. Distributions of demographic and clinical variables by
statin status are shown in Table 1. The sample was predominantly male. Statin initiators
were predominantly commercially-insured, whereas statin non-initiators were as likely to be
covered by Medicare or commercial insurance. Variables were generally well-balanced
across treatment groups, with the notable exceptions that initiators: received more cardiac
stress tests or angiograms; had more diagnoses of hyperlipidemia and ischemic heart
disease; and to co-initiated more other cardiovascular medications. While these
characteristics may be associated with increased CVD risk, in claims data all of these factors
may also be seen as markers of better disease management, preventive healthcare utilization,
or pre-operative care.
Post-CABG AKI codes occurred in 871 (6.2%) non-initiators and 104 (3.4%) initiators.
Unadjusted regression models yielded a highly-protective effect measure estimate, but
adjustment attenuated the estimate to RR=0.78 (95% CI: 0.63, 0.96) (see Table 2). When the
analysis was repeated with trimmed IPTW weighted models and PS matching, the results
were very similar (see Table 2).
However, when stratifying the effect measure estimates by age, the relative protective effect
was more pronounced in individuals aged < 65 years than older individuals (see Table 3).
AKI was much more common in the older age group (7.7%) than the younger age group
(4.0%). No differences were seen in other subgroups.
When the length of exposure window before CABG was varied, the effect measure estimate
remained constant. Additionally, when a wider definition of kidney failure was employed,
the results remained essentially unchanged (see Table 2).
When the analysis was repeated considering beta-blocker initiation in the place of statin
initiation, we observed no protective effect of beta blockers initiation against post-CABG
AKI, with multivariable adjusted models yielding RR=0.96 (95% CI: 0.84, 1.10) and IPTW
models yielding RR=1.02 (95% CI: 0.87, 1.19).
Discussion
In this cohort study of over 17,000 patients, we found that initiation of a statin prior to non-
emergent CABG surgery was associated with a reduced risk of post-surgical AKI. The
results were robust throughout sensitivity analyses and estimation methods.
We observed effect measure modification by age. The protective effect was much more
pronounced in younger individuals. However, those under 65 years experienced many fewer
post-CABG AKI events overall, suggesting that the absolute benefit of statin treatment may
not be as large as the RR suggests23.
Statins lower low-density lipoprotein cholesterol, reducing the risk of CVD. Randomized
trials have also demonstrated that peri-operative statin use is associated with decreased
myocardial ischemia24 and atrial fibrillation25, which could indirectly benefit kidney
function by maintaining renal perfusion during and immediately following surgery.
However, the elderly are at higher AKI risk for a variety of reasons26, and statins’ benefit
may be diluted in such an at-risk population.
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Other estimates of the effect of peri-operative statin use on post-operative AKI have ranged
from strongly protective8 to null4,10,13. Our estimate is comparable to other studies of the
subject3,14, but differs from the null result of a recent, small randomized trial10 restricted to
high-AKI risk patients. We saw little protective effect in older patients, but observed the
protective effect primarily in the younger, low-risk patients, which could explain the
difference in results.
Non-randomized studies of preventive medications are potentially subject to bias which can
inflate protective effect measure estimates. Yet, through the implementation of a rigorous
methodology, our study helps to more accurately quantify the potential benefit of statins in 4
ways. First, we adopted a design explicitly aimed at minimizing the healthy user effect, a
potentially important bias in non-experimental statin studies. We restricted our study to new
users who initiated a statin immediately prior to surgery and compared these with patients
not initiating a statin, removing bias created by comparing long-term, adherent users to non-
users.
Second, we excluded emergency CABG surgeries, resulting in a relatively homogeneous
patient population of those with planned CABG surgeries. We speculated that statin
initiation in these patients would be more dependent on physician preference or protocol
than clinical factors or patient characteristics.
Third, we adjusted for a wide array of clinical characteristics, including complexity of
surgery. Prevalent medication use and concurrent medication initiation were considered as
separate covariates. Prevalent medication use was very similar between the 2 treatment
groups, but statin initiators tended to co-initiate other medications more frequently. While
statin initiation immediately prior to surgery may be indicative of more aggressive disease
management or access to care, considering other peri-operative medication initiation
allowed us to more accurately assess pre-operative care and adjust for differences which
may exist between the treatment groups.
Lastly, we examined the effect of beta-blocker initiation on post-CABG AKI as a negative
control. Beta blocker initiation was not associated with a reduced AKI risk, suggesting the
observed effect estimate among the statin users may be a real effect, not simply unmeasured
behavioral or clinical factors for which any medication initiation serves as a proxy27.
Nevertheless, these study findings should be interpreted in the context of the following
limitations. First, despite our attempts to create comparable treatment groups, we observed
differences—e.g. more healthcare utilization, CVD management, and concurrent medication
initiation—among the statin users which may indicate better health status, or healthcare
quality and access, and thus potentially better outcomes among statin users. Although we
controlled for these observed factors in our analysis, the potential for unmeasured
confounding remains. For example, measures of baseline glomerular function are
unavailable in claims; diagnosis codes for CKD and number of procedure claims for
measures of glomerular function were used as proxies, but they may not fully capture
baseline renal impairment, which is a strong risk factor for AKI28. However, while
glomerular function is a strong predictor of AKI, it is not obviously a predictor of statin
initiation, and therefore may not be a strong confounder of the association.
Secondly, some of the included variables have been shown to have poor validity, such as
CKD29 which would allow for some residual confounding by baseline renal impairment to
remain. Similarly, the sensitivity AKI billing codes has been shown to be very poor, yet the
specificity is very high29. While the insensitive AKI definition may underestimate true AKI
occurrence, under the assumption of nondifferential misclassification of the outcome
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between the treatment groups, relative effect measures, such as the RRs calculated in this
study, should be unbiased30.
Third, these results may not be generalizable to all CABG patients. The majority of patients
undergoing CABG were prevalent statin users, and many others had urgent or emergency
surgeries, thus not meeting our inclusion criteria. However, emergency CABG patients
likely do not have time to initiate a statin prior to surgery. The resulting patients are those of
most interest: it is among statin naive patients that statin intervention is possible and the
potential benefits of initiation need to be determined.
As researchers continue to investigate and suggest additional protective and beneficial statin
effects, careful consideration must be given to the designs of non-experimental studies to
ensure they are not subject to common biases in studies of preventive medications. After
considering the timing of statin initiation, observing the entire length of statin treatment,
measuring important markers of pre-clinical care such as medication initiation, and
matching non-users to users on healthcare utilization, our study supports the hypothesis that
prescribing a statin prior to CABG in those not already receiving statin therapy may
modestly attenuate the incidence of post-CABG AKI, particularly among younger patients.
While many CABG patients will already be receiving statin therapy, those not yet receiving
it may benefit from initiation prior to surgery.
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Cohort schematics for pre-coronary artery bypass graft statin initiation
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Distribution of statin initiation by day prior to CABG surgery
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Table 1
Baseline demographics and clinical characteristics by statin initiation status
Variable Statin non-initiator (n=13,992) Statin initiator (n=3,085)
Male 10,394 (74.3%) 2,453 (79.5%)
Mean age, standard deviation (SD) 65.4 (11.0) (62.5) (10.0)
MarketScan Database
 Commercial Claims and Encounters Database 7,135 (51.0%) 1,978 (64.1%)
 Medicare Supplementary Database 6,857 (49.0%) 1,107 (35.9%)
HEALTHCARE UTILIZATION
Mean day of hospitalization on which CABG is performed (SD) 0.88 (1.26) 0.49 (0.99)
Mean number of lipid tests (SD)* 0.68 (1.11) 0.84 (1.12)
Mean number of creatinine measurements (SD)* 0.04 (0.37) 0.03 (0.25)
Mean number of hospitalizations (SD)* 0.67 (0.76) 0.47 (0.70)
Mean number of emergency department visits (SD)* 0.14 (0.49) 0.11 (0.43)
CARDIOVASCULAR DISEASE MANAGEMENT
Angiography performed 10,492 (75.0%) 2,634 (85.4%)
Cardiac stress test performed 8,381 (59.9%) 2,166 (70.2%)
Echocardiograph 8,030 (57.4%) 1,723 (55.9%)
CARDIOVASCULAR & COMORBID CONDITIONS
Number of vessels bypassed during surgery
 1–2 5,265 (37.6%) 951 (30.8%)
 3–5 7,565 (54.1%) 1,779 (57.7%)
 6+ 862 (6.2%) 259 (8.4%)
Diabetes mellitus 4,170 (29.8%) 813 (26.4%)
Chronic kidney disease 109 (0.8%) 13 (0.4%)
Other kidney disease
Proteinuria 70 (0.5%) 13 (0.4%)
Hypertension 7,208 (51.5%) 1,596 (51.7%)
Hyperlipidemia 4,550 (32.5%) 1,283 (41.6%)
Other ischemic heart disease 12,811 (91.6%) 2,972 (96.3%)
Atrial fibrillation 1,422 (10.2%) 163 (5.3%)
ACUTE EVENTS IN PREVIOUS 6 MONTHS
Recent myocardial infarction† 484 (3.5%) 108 (3.5%)
History of myocardial infarction 364 (2.6%) 83 (2.7%)
Unstable angina† 1,743 (12.5%) 464 (15.0%)
Stroke 3,723 (26.6%) 746 (24.2%)
Insertion of a coronary stent 236 (1.7%) 51 (1.7%)
Angioplasty 228 (1.6%) 50 (1.6%)
PREVALENT MEDICATION USE DURING BASELINE
Angiotensin converting enzyme inhibitors 4,349 (31.1%) 916 (29.7%)
Angiotensin receptor blockers 2,212 (15.8%) 434 (14.1%)
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Variable Statin non-initiator (n=13,992) Statin initiator (n=3,085)
Beta blockers 4,981 (35.6%) 982 (31.8%)
Calcium channel blockers 3,219 (23.0%) 607 (19.7%)
Anti-platelet agents 1,497 (10.7%) 231 (7.5%)
Alpha blockers 1,324 (9.5%) 200 (6.5%)
Thiazide diuretics 3,215 (23.0%) 675 (21.9%)
Potassium-sparing diuretics 880 (6.3%) 124 (4.0%)
Loop diuretics 1,794 (12.8%) 210 (6.8%)
Niacin 250 (1.8%) 36 (1.2%)
Fibrates 976 (7.0%) 150 (4.9%)
Ezetimibe 637 (4.6%) 85 (2.8%)
Anti-coagulants 1,031 (7.4%) 106 (3.4%)
NSAIDs 2,612 (18.7%) 562 (18.2%)
MEDICATIONS INITIATED DURING EXPOSURE WINDOW
Angiotensin converting enzyme inhibitors 1,410 (10.1%) 606 (19.6%)
Angiotensin receptor blockers 573 (4.1%) 189 (6.1%)
Beta blockers 2,832 (20.2%) 1,498 (48.6%)
Calcium channel blockers 928 (6.6%) 306 (9.9%)
Anti-platelet agents 549 (3.9%) 253 (8.2%)
Alpha blockers 546 (3.9%) 248 (8.0%)
Thiazide diuretics 839 (6.0%) 246 (8.0%)
Potassium-sparing diuretics 249 (1.8%) 52 (1.7%)
Loop diuretics 634 (4.5%) 106 (3.4%)
Niacin 69 (0.5%) 49 (1.6%)
Fibrates 264 (1.9%) 57 (1.9%)
Ezetimibe 143 (1.0%) 176 (5.7%)
Anti-coagulants 308 (2.2%) 47 (1.5%)
NSAIDs 456 (3.3%) 78 (2.5%)
*
Occurring within the 200 days prior to admission for CABG surgery
†
Not including events which occurred in the 20 days prior to hospital admission for CABG as those patients were excluded
NSAIDS – Non-steroidal anti-inflammatory drugs
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